1. Generics Bulletin
  2. >>Leadership

Who’s Hired? EuroAPI Gets Another New CEO

As Hyloris Installs A Fresh CFO And Stada Gets New IR Head

 
• By Dave Wallace

EuroAPI says it is moving “into a new chapter” after appointing another new CEO, marking the latest change in leadership after what has been a turbulent year for the European active pharmaceutical ingredients specialist.

The baton has been passed once again at EuroAPI (Shutterstock)

European active pharmaceutical ingredients specialist EuroAPI says it has moved “into a new chapter” for the company after appointing David Seignolle as its new chief executive officer and Emmanuel Blin as chair of the board of directors.

Seignolle replaces as CEO Ludwig de Mot, who had only taken up the role this year after initially joining the company as chief transformation officer in January 2024. This came after a turbulent period for the company that saw former CEO Karl Rotthier

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.